{"id":"W4404435807","doi":"10.17615/d5s2-9s76","title":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; bluebird bio; Alexion Pharmaceuticals; Pharmacyclics; Novavax; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Takeda Oncology; AstraZeneca; Genentech; MorphoSys; Syndax Pharmaceuticals; Seagen; CTI Biopharma; CareDx; BeiGene; Juno Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; Atara Biotherapeutics; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; MEI Pharma; Omeros Corporation; Karyopharm Therapeutics; HistoGenetics; Gateway for Cancer Research; Celgene; Mallinckrodt Pharmaceuticals; Spectrum Pharmaceuticals; Actinium Pharmaceuticals; Gilead Sciences; TG Therapeutics; Sanofi; Kiadis Pharma; GlaxoSmithKline; aTyr; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; Vertex Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation; Incyte; Pfizer","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; Immunology; B cell; Bone marrow; Antigen; T cell; Antibody; Immune system","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001565752,0.0003437036,0.0004008227,0.0005036293,0.0006591285,0.001030604,0.0009265,0.0005334012,0.004068464],"category_scores_gemma":[0.0005912723,0.0001830071,0.0002991029,0.0005069333,0.0004281878,0.000686756,0.0004368594,0.00104949,0.0006018689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009984965,"about_ca_system_score_gemma":0.002278632,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001698513,"about_ca_topic_score_gemma":0.002610988,"domain_scores_codex":[0.9995617,0.0001517693,0.00002011419,0.00007246896,0.0001015079,0.00009230619],"domain_scores_gemma":[0.9996,0.00008519297,0.00003093959,0.00008127154,0.00004529693,0.0001573545],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04707116,0.01596935,0.03646065,0.00030322,0.0003676424,0.004264253,0.0004193464,0.003349136,0.2274184,0.01444873,0.01907677,0.6308514],"study_design_scores_gemma":[0.03128055,0.1054619,0.2810968,0.0002530924,0.001873275,0.02941578,0.0008684935,0.03548614,0.3648143,0.006513192,0.1426982,0.0002383488],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9625085,0.004278778,0.008802326,0.00354483,0.0001522798,0.0007862416,0.0008133778,0.0003983639,0.01871539],"genre_scores_gemma":[0.9816942,0.001876989,0.009759136,0.0008771159,0.0001141597,0.0002530423,0.0009567229,0.0001248677,0.004343891],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004068464,"threshold_uncertainty_score":0.01361036,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0441716723019166,"score_gpt":0.3254826321958296,"score_spread":0.281310959893913,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}